UnknownNot Applicable

Pediatric and Adult Registry for Patients With ARThrogryposis

France230 participantsStarted 2021-11-01

Plain-language summary

The aim of the study is Epidemiological Evaluation of a single-centre national cohort of patients with Arthrogryposis multiplex congenita (AMC)

Who can participate

Age range

90 Years

Sex

ALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion criteria

. Patients diagnosed with arthrogryposis multiplex congenita prenatally or postnatally seen at least once at the reference center from January 2008 to July 2023.
. pediatric and adult individuals.
. Addressed to the reference centre of the University Hospital Grenoble Alpes.
. living in France.

Exclusion criteria

. Individuals who did not consent to use their data (or the data of their children).
. Individuals with less than two affected joint levels.
. Individuals under guardianship or deprived of liberty.
. Inability to collect comprehensive medical information (individuals recently arrived in France)

Questions worth asking your doctor

Bring these to your next appointment. They're a starting point for a shared conversation — not a sign you qualify or a recommendation to enrol.

1Based on my diagnosis and history, is this trial worth exploring for me — or is there a standard treatment we should try first?
2What does this trial's phase tell us about how much is already known about its safety and benefit?
3What would taking part actually involve for me — visits, tests, time, and travel?
4What are the known and possible risks or side effects I should weigh, and how would they be monitored?
5If this trial isn't the right fit, what other options or trials would you suggest I look into?

Generated to help you prepare — always confirm anything about your own eligibility and care with the study team and your doctor.

Questions for the trial coordinator

The trial coordinator is the person who runs the study day to day. These cover the practical side — logistics, costs, and what taking part would actually mean for your life. The study team confirms whether you meet the criteria; these are questions to ask, not a sign you qualify.

1What does taking part actually involve week to week — how many visits, where, and how long does each one take?
2What costs are covered by the study, and what might I have to pay for myself, including travel, parking, or time off work?
3What happens during screening, and what happens if the study team confirms I don't meet the criteria after those tests?
4Who pays for the scans, blood work, and other tests the trial requires — the study, my insurance, or me?
5How will being in the trial affect my regular care, and will my own doctor stay informed and involved?
6Can I leave the trial at any point if I change my mind, and what would happen to my care if I do?

A starting point for the conversation — always confirm anything about your own eligibility, costs, and care with the study team and your doctor.

What they're measuring

Frequency of etiologies

Timeframe: 2 years

Trial details

NCT IDNCT05673265

SponsorUniversity Hospital, Grenoble

Sponsor typeOTHER

Study typeOBSERVATIONAL

Primary completion2023-07-01

Contact for this trial

Sarah UNEISI, PharmD

0476768709 SUneisi@chu-grenoble.fr

View on ClinicalTrials.gov More Arthrogryposis Multiplex Congenita (AMC) trials